Key result
Direct oral anticoagulants could represent a more appealing alternative to low-molecular-weight heparin in paraneoplastic venous thrombosis, with emerging studies proving similar efficacy and safety.
Why the study?
Data on VTE treatment and prophylaxis in cancer patients are limited, with many recommendations extrapolated from non-cancer cohorts, and limited data exist on direct oral anticoagulants in paraneoplastic VTE.
Do direct oral anticoagulants provide similar efficacy and safety compared to low-molecular-weight heparin in patients with cancer-associated venous thromboembolism?
Design
Review
Authors
Loading...
Does not support switching to DOACs for cancer-associated VTE yet; leaves open the need for dedicated randomized comparisons.
Do direct oral anticoagulants provide similar efficacy and safety compared to low-molecular-weight heparin in patients with cancer-associated venous thromboembolism?
This review highlights the need for more dedicated studies on direct oral anticoagulants for VTE in cancer patients, as current recommendations are largely extrapolated from non-cancer cohorts.
Iorga et al. (2019) conducted a review in Venous thromboembolism in cancer patients. Anticoagulation therapy (LMWH, DOACs, UFH, VKAs) was evaluated. Direct oral anticoagulants could represent a more appealing alternative to low-molecular-weight heparin in paraneoplastic venous thrombosis, with emerging studies proving similar efficacy and safety.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: